These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1168 related articles for article (PubMed ID: 28117005)

  • 1. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.
    Berinstein E; Levy A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):973-983. PubMed ID: 28792790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PHARMACOGENOMIC DETERMINANTS OF RESPONSE TO CARDIOVASCULAR DRUGS.
    Stankov KM; Stanimirov BG; Mikov MM
    Med Pregl; 2015; 68(7-8):259-65. PubMed ID: 26591639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use.
    de Denus S; Dubé MP; Tardif JC
    Expert Opin Pharmacother; 2015; 16(17):2549-52. PubMed ID: 26371722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner.
    Sleder AT; Kalus J; Lanfear DE
    J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):20-6. PubMed ID: 26054891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics in cardiovascular disorders: an update on the principal drugs.
    Predazzi IM; Mango R; Norata GD; Di Daniele N; Sergi D; Romeo F; Novelli G
    Am J Cardiovasc Drugs; 2013 Apr; 13(2):79-85. PubMed ID: 23539170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Commentary: Should Pharmacogenomic Evidence Be Considered in Clinical Decision Making? Focus on Select Cardiovascular Drugs.
    Bottorff MB; Bright DR; Kisor DF
    Pharmacotherapy; 2017 Sep; 37(9):1005-1013. PubMed ID: 28654154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenges of implementing pharmacogenomic testing in the clinic.
    Moyer AM; Caraballo PJ
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):567-577. PubMed ID: 28949250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of pharmacogenomics in elderly patients treated for cardiovascular diseases.
    Božina N; Vrkić Kirhmajer M; Šimičević L; Ganoci L; Mirošević Skvrce N; Klarica Domjanović I; Merćep I
    Croat Med J; 2020 Apr; 61(2):147-158. PubMed ID: 32378381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular pharmacogenomics and individualized drug therapy.
    Pereira NL; Weinshilboum RM
    Nat Rev Cardiol; 2009 Oct; 6(10):632-8. PubMed ID: 19707183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Management of Cardiovascular Disorders.
    Jain KK
    Med Princ Pract; 2017; 26(5):399-414. PubMed ID: 28898880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ubiquitous Pharmacogenomics (U-PGx): The Time for Implementation is Now. An Horizon2020 Program to Drive Pharmacogenomics into Clinical Practice.
    Cecchin E; Roncato R; Guchelaar HJ; Toffoli G;
    Curr Pharm Biotechnol; 2017; 18(3):204-209. PubMed ID: 28044932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.
    Terra SG; Johnson JA
    Am J Cardiovasc Drugs; 2002; 2(5):287-96. PubMed ID: 14727958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics in Cardiovascular Medicine.
    Weeke PE
    Adv Pharmacol; 2018; 83():333-360. PubMed ID: 29801582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Personalised Healthcare: The DiMA Clinical Model.
    Borro M; Gentile G; Cipolloni L; Foldes-Papp Z; Frati P; Santurro A; Lionetto L; Simmaco M
    Curr Pharm Biotechnol; 2017; 18(3):242-252. PubMed ID: 28183244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Applications of Personalized Medicine: A New Paradigm and Challenge.
    Di Sanzo M; Cipolloni L; Borro M; La Russa R; Santurro A; Scopetti M; Simmaco M; Frati P
    Curr Pharm Biotechnol; 2017; 18(3):194-203. PubMed ID: 28240172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. En route to precision medicine through the integration of biological sex into pharmacogenomics.
    Gaignebet L; Kararigas G
    Clin Sci (Lond); 2017 Feb; 131(4):329-342. PubMed ID: 28159880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics of cholesterol-lowering therapy.
    Schmitz G; Langmann T
    Vascul Pharmacol; 2006 Feb; 44(2):75-89. PubMed ID: 16337220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.
    Cordero A; Rodriguez Padial L; Batalla A; López Barreiro L; Torres Calvo F; Castellano JM; Ruiz E; Bertomeu-Martínez V;
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27957818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular Pharmacogenomics--Implications for Patients With CKD.
    Cavallari LH; Mason DL
    Adv Chronic Kidney Dis; 2016 Mar; 23(2):82-90. PubMed ID: 26979147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 59.